The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Humacyte Inc
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Humacyte, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
bovnews7d
What’s Behind the 4.24% Gain in Humacyte Inc (HUMA) Stock? Find Out Now!
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 19.40% ...
Morningstar7d
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
Humacyte, Inc. (HUMA) Securities Class Action: The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s business, operations ...
Yahoo Finance3d
Humacyte, Inc. (HUMA)
DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
Business Wire10d
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Act…
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...
bovnews12d
What’s Causing Humacyte Inc (HUMA) Stock’s -40.24% Drop Over the Last Six Months?
On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...
Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...
The Business Journals23d
Shareholder lawsuit shines light on biotech's FDA woes
Shareholders accuse Humacyte of misleading investors about quality issues. STORY HIGHLIGHTS Shareholders accuse Humacyte of misleading investors about quality issues. Humacyte's stock fell after ...
Enid News & Eagle17d
Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the ...
Nasdaq15d
Humacyte (HUMA) Insiders Show Confidence Despite Stock Decline
Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon ...
The Bakersfield Californian19d
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action
SAN DIEGO, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte ...